- Home
- PEBK vs GALT Comparison
PEBK vs GALT Comparison
Compare PEBK & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEBK | GALT |
|---|---|---|
| Founded | 1912 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.0M | 199.2M |
| IPO Year | 2012 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PEBK | GALT |
|---|---|---|
| Price | $41.00 | $2.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 28.2K | ★ 337.9K |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | 21.48 | ★ 36.84 |
| EPS | ★ 3.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.14 | $1.22 |
| 52 Week High | $42.63 | $7.13 |
Technical Indicators
Market Signals| Indicator | PEBK | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 41.58 |
| Support Level | $35.24 | $2.13 |
| Resistance Level | $42.36 | $3.32 |
| Average True Range (ATR) | 0.94 | 0.22 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 46.96 | 16.22 |
Price Performance
Historical ComparisonAbout PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.